Literature DB >> 17558469

Angiotensin-converting enzyme 2 in acute respiratory distress syndrome.

Y Imai1, K Kuba, J M Penninger.   

Abstract

Angiotensin-converting enzyme (ACE) and ACE2 are highly homologous metalloproteases that provide essential catalytic functions in the renin-angiotensin system (RAS). Angiotensin II is one key effector peptide of the RAS, inducing vasoconstriction and exerting multiple biological functions. ACE cleaves angiotensin I to generate angiotensin II, whereas ACE2 reduces angiotensin II levels. Accumulating evidence has demonstrated a physiological and pathological role of ACE2 in the cardiovascular systems. Intriguingly, the SARS coronavirus, the cause of severe acute respiratory syndrome (SARS), utilizes ACE2 as an essential receptor for cell fusion and in vivo infections. Moreover, recent studies have demonstrated that ACE2 protects murine lungs from acute lung injury as well as SARS-Spike protein-mediated lung injury, suggesting a dual role of ACE2 in SARS infections and protection from ARDS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17558469      PMCID: PMC7079778          DOI: 10.1007/s00018-007-6228-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  53 in total

1.  Angiotensin-converting enzyme insertion/deletion polymorphism is associated with severe hypoxemia in pediatric ARDS.

Authors:  Pablo Cruces; Franco Díaz; Alonso Puga; Benjamín Erranz; Alejandro Donoso; Cristóbal Carvajal; Jan Wilhelm; Gabriela M Repetto
Journal:  Intensive Care Med       Date:  2011-10-18       Impact factor: 17.440

2.  Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.

Authors:  Yoriko Yamazato; Anderson J Ferreira; Kwon-Ho Hong; Srinivas Sriramula; Joseph Francis; Masanobu Yamazato; Lihui Yuan; Chastity N Bradford; Vinayak Shenoy; Suk P Oh; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

3.  COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Authors:  Megan H St John; Arden R Barry
Journal:  Can Pharm J (Ott)       Date:  2020-06-14

4.  Association of IL-10-1082 G/G genotype with lower mortality of acute respiratory distress syndrome in a Chinese population.

Authors:  Xiaodong Jin; Zhi Hu; Yan Kang; Chang Liu; Yongfang Zhou; Xiaodong Wu; Jin Liu; Mingxing Zhong; Chuanxing Luo; Lijing Deng; Yiyun Deng; Xiaoqi Xie; Zhongwei Zhang; Yan Zhou; Xuelian Liao
Journal:  Mol Biol Rep       Date:  2011-10-28       Impact factor: 2.316

5.  Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection.

Authors:  Xiang Gao; Shengyuan Zhang; Jizhou Gou; Yanling Wen; Lujie Fan; Jian Zhou; Guangde Zhou; Gang Xu; Zheng Zhang
Journal:  J Infect       Date:  2022-07-03       Impact factor: 38.637

6.  Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection.

Authors:  Antonio Vitiello; Francesco Ferrara
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

Review 7.  Protease regulation: the Yin and Yang of neural development and disease.

Authors:  Ge Bai; Samuel L Pfaff
Journal:  Neuron       Date:  2011-10-06       Impact factor: 17.173

Review 8.  JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations.

Authors:  Rahma Menshawey; Esraa Menshawey; Ayman H K Alserr; Antoine Fakhry Abdelmassih
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-10-15

Review 9.  ACE2, a promising therapeutic target for pulmonary hypertension.

Authors:  Vinayak Shenoy; Yanfei Qi; Michael J Katovich; Mohan K Raizada
Journal:  Curr Opin Pharmacol       Date:  2011-01-05       Impact factor: 5.547

10.  Interaction of a specific population of human embryonic stem cell-derived progenitor cells with CD11b+ cells ameliorates sepsis-induced lung inflammatory injury.

Authors:  Sophie P Toya; Fei Li; Marcelo G Bonini; Ignatius Gomez; Mao Mao; Kurt W Bachmaier; Asrar B Malik
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.